Atlanta, GA 6/25/12 (StreetBeat) -- Sanguine Corp. (OTCBB:SGUI) is pleased to provide a corporate update in the form of a statement from the President of the Company, Mr. Frank Marra.
As an emerging life science technology company, we have overcome several obstacles over these past few years, all of which were exacerbated by the meltdown of the financial markets. However, in the face of these issues we have made substantial strides in furthering our research and development protocols and objectives, and now look to move forward on a number of fronts that we believe offer us the most significant opportunities for regulatory approval. To that end, we continue to be focused on the development of proprietary and novel PFC-based therapies for some of the most troubling unmet medical needs. We have incorporated both a long-term staged growth strategy along with a short term partnership and licensing model to maximize growth potential.
We intend to achieve our designated objectives through two primary means: (1) the organic development, and (2) strategic alliances through carefully managed partnerships with well positioned companies, universities, research institutions and government agencies. As part of this strategy we plan on rounding out our medical advisory board by adding strategic key opinion leaders in the fields of PFC research and life science product development. Furthermore, we look to also grow the company through the acquisition of synergistic and complementary technologies that we feel add value to our product and to our shareholders.
Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail email@example.com or call (662) 392-0740 for pricing and scheduling.